XZP-KM257

N/A

Report date: 2024/11/29 20:00:39

Base Information

Drug NameXZP-KM257
Drug Alias Name重组抗HER2结构域Ⅱ和结构域Ⅳ双特异性抗体注射液XZP-KM257KM-257
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Kangming Bio New Drug Development Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesXuanzhu (HK) Biopharmaceutical Ltd
Inactive CompaniesBeijing Xuanzhu Kangming Biotechnology Co LtdXuanzhu (Shijiazhuang) Biotechnology Co Ltd
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A